TCS gene delivery systems - Inex Pharmaceuticals/Protiva Biotherapeutics

Drug Profile

TCS gene delivery systems - Inex Pharmaceuticals/Protiva Biotherapeutics

Latest Information Update: 17 Jun 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inex Pharmaceuticals Corporation; Protiva Biotherapeutics
  • Class Small interfering RNA
  • Mechanism of Action Immunostimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Jun 2002 Discontinued - Preclinical for Cancer in Canada (Parenteral)
  • 05 Nov 1997 Preclinical development for Cancer in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top